SCHEMBL70926

SCHEMBL70926

O=C(O)CNC(=O)c1cc(-c2ccc(Cl)s2)[nH]n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.58
NPSR1 Q6W5P4 1/20 0.58
POLB P06746 9/20 0.54
KMT2A Q03164 5/20 0.53
MEN1 O00255 3/20 0.53
TDP1 Q9NUW8 1/20 0.53
MAPT P10636 8/20 0.53
ALDH1A1 P00352 4/20 0.53
MAPK1 P28482 1/20 0.53
BLM P54132 1/20 0.52
KDM4E B2RXH2 4/20 0.50
LMNA P02545 4/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2D6 P10635 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
HTT P42858 1/20 0.50
TNIK Q9UKE5 1/20 0.44
HTR2A P28223 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL72067 0.81 L3MBTL1 (0.65) L3MBTL1NPSR1POLBKMT2AMEN1
SCHEMBL69243 0.76 RAB9A (0.50) POLBMAPTALDH1A1LMNASMN1; SMN2
SCHEMBL71738 0.73 EGLN1 (0.51) L3MBTL1MAPK1LMNAHTTSMN1; SMN2
SCHEMBL1221861 0.72 ALOX15 (0.49) L3MBTL1KMT2AMEN1MAPTMAPK1
SCHEMBL71764 0.70 EGLN3 (0.49) KMT2AALDH1A1CYP1A2SMN1; SMN2EGLN1
SCHEMBL4062009 0.69 L3MBTL1 (0.56) L3MBTL1NPSR1POLBKMT2AMEN1
SCHEMBL1106560 0.69 KMT2A (0.65) POLBKMT2AMEN1TDP1ALDH1A1
SCHEMBL70869 0.68 NOTUM (0.43) NPSR1KMT2ATDP1MAPTALDH1A1
SCHEMBL70294 0.68 HPGD (0.56) NPSR1KMT2AMEN1MAPTALDH1A1
SCHEMBL70310 0.66 IDO1 (0.47) L3MBTL1NPSR1POLBKMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129376-B2 Piperidine derivatives as inhibitors of stearoyl-CoA desaturase AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) 2012-03-06 US disclosed
EP-2268143-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE Forest Laboratories Holdings Limited (BM) 2011-01-05 EP disclosed
WO-2009117676-A2 NOVEL PIPERIDINE DERIVATIVES AS INHIBITORS OF STEAROYL-COA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 WO disclosed
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE FOREST LABORATORIES HOLDINGS LIMITED (BM) 2009-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239810-A1 NOVEL PIPERAZINE DERIVATIVES AS INHIBITORS OF STEAROYL-CoA DESATURASE SCD, SCD5, FADS2 L3MBTL1 4379/4885NPSR1 3026/4885POLB 1727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.